1. Home
  2. DTIL
  3. DTIL News

Latest Precision BioSciences Inc. (DTIL) News on February 22, 2025

DTIL

Argus Research

a day ago

Daily – Vickers Top Insider Picks for 02/21/2025

Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV
DTIL

Clinical Trials Arena

2 days ago

Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV

DTIL

Argus Research

2 days ago

Daily – Vickers Top Insider Picks for 02/20/2025

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
DTIL

Benzinga

3 days ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
DTIL

Business Wire

3 days ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

DTIL

Argus Research

3 days ago

Daily – Vickers Top Insider Picks for 02/19/2025

DTIL

Argus Research

4 days ago

Daily – Vickers Top Insider Picks for 02/18/2025

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
DTIL

Business Wire

24 days ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

DTIL

MT Newswires

a month ago

Precision BioSciences Shares Up After Upgrade From BMO Capital, Positive Date From Gene Therapy Study

DTIL

MT Newswires

a month ago

BMO Capital Upgrades Precision BioSciences to Outperform From Market Perform, Price Target is $34

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
DTIL

Business Wire

a month ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
DTIL

Business Wire

a month ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

DTIL

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 01/03/2025

DTIL

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 12/31/2024

Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial
DTIL

Clinical Trials Arena

2 months ago

Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
DTIL

Business Wire

2 months ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming November Investor Conferences
DTIL

Business Wire

3 months ago

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
DTIL

Business Wire

3 months ago

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
DTIL

Zacks

4 months ago

Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates

DTIL

Associated Press Finance

4 months ago

Precision BioSciences: Q3 Earnings Snapshot

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
DTIL

Business Wire

4 months ago

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
DTIL

Zacks

4 months ago

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?

Precision BioSciences to Report Third Quarter Results on November 4, 2024
DTIL

Business Wire

4 months ago

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
DTIL

Business Wire

4 months ago

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
DTIL

Business Wire

4 months ago

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Precision BioSciences to Report Q3 Earnings: What's in the Cards?
DTIL

Zacks

4 months ago

Precision BioSciences to Report Q3 Earnings: What's in the Cards?

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
DTIL

Business Wire

4 months ago

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
DTIL

Business Wire

4 months ago

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
DTIL

Business Wire

4 months ago

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
DTIL

Zacks

5 months ago

Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
DTIL

Business Wire

5 months ago

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

DTIL

MT Newswires

5 months ago

Precision BioSciences Submits Clinical Trial Applications for Hepatitis B Treatment

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
DTIL

Business Wire

5 months ago

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DTIL

Business Wire

5 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
DTIL

Zacks

5 months ago

Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
DTIL

Business Wire

5 months ago

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
DTIL

Zacks

5 months ago

Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
DTIL

Business Wire

6 months ago

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
DTIL

Business Wire

6 months ago

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
DTIL

Zacks

6 months ago

Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade

FDA grants IND clearance for TG Therapeutics’ trial of multiple sclerosis treatment
DTIL

Clinical Trials Arena

6 months ago

FDA grants IND clearance for TG Therapeutics’ trial of multiple sclerosis treatment

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
DTIL

Business Wire

6 months ago

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
DTIL

Zacks

7 months ago

Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates

DTIL

Associated Press Finance

7 months ago

Precision BioSciences: Q2 Earnings Snapshot

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
DTIL

Business Wire

7 months ago

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences to Participate in Upcoming August Investor Conferences
DTIL

Business Wire

7 months ago

Precision BioSciences to Participate in Upcoming August Investor Conferences

Precision BioSciences to Report Second Quarter Results on August 1, 2024
DTIL

Business Wire

7 months ago

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
DTIL

Business Wire

7 months ago

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Precision BioSciences Announces its Addition to the Russell Microcap® Index
DTIL

Business Wire

8 months ago

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
DTIL

Business Wire

8 months ago

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
DTIL

Business Wire

8 months ago

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
DTIL

Business Wire

9 months ago

Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress

Precision BioSciences to Participate in Upcoming June Investor Conferences
DTIL

Business Wire

9 months ago

Precision BioSciences to Participate in Upcoming June Investor Conferences

Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
DTIL

Zacks

9 months ago

Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DTIL

Business Wire

9 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DTIL

Associated Press Finance

9 months ago

Precision BioSciences: Q1 Earnings Snapshot

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
DTIL

Business Wire

9 months ago

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DTIL

Business Wire

9 months ago

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

Precision BioSciences to Report First Quarter Results on May 13, 2024
DTIL

Business Wire

9 months ago

Precision BioSciences to Report First Quarter Results on May 13, 2024

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
DTIL

Business Wire

10 months ago

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
DTIL

Business Wire

10 months ago

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
DTIL

Zacks

10 months ago

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
DTIL

Business Wire

10 months ago

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
DTIL

Zacks

10 months ago

Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?

Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
DTIL

Zacks

a year ago

Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
DTIL

Zacks

a year ago

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
DTIL

Zacks

a year ago

Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates

DTIL

Associated Press Finance

a year ago

Precision BioSciences: Q4 Earnings Snapshot

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
DTIL

Business Wire

a year ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
DTIL

Business Wire

a year ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
DTIL

Business Wire

a year ago

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
DTIL

Business Wire

a year ago

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
DTIL

Business Wire

a year ago

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
DTIL

Business Wire

a year ago

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants

Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
DTIL

Zacks

a year ago

Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
DTIL

Business Wire

a year ago

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
DTIL

Business Wire

a year ago

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
DTIL

Business Wire

a year ago

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
DTIL

Business Wire

a year ago

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

Precision BioSciences to Effect a Reverse Stock Split
DTIL

Business Wire

a year ago

Precision BioSciences to Effect a Reverse Stock Split

SAB Biotherapeutics Announces Executive Leadership Change
DTIL

GlobeNewswire

a year ago

SAB Biotherapeutics Announces Executive Leadership Change

DTIL

Associated Press Finance

a year ago

Bank7: Q4 Earnings Snapshot

Bank7 Corp. Announces Q4 2023 and Full Year Earnings
DTIL

PR Newswire

a year ago

Bank7 Corp. Announces Q4 2023 and Full Year Earnings

Advanced Emissions Solutions Signs Contract for Construction of Granular Activated Carbon Expansion at Red River Plant with Wieland
DTIL

GlobeNewswire

a year ago

Advanced Emissions Solutions Signs Contract for Construction of Granular Activated Carbon Expansion at Red River Plant with Wieland

Advanced Emissions Solutions to Rebrand as Arq, Inc.
DTIL

GlobeNewswire

a year ago

Advanced Emissions Solutions to Rebrand as Arq, Inc.

Caledonia Mining Corporation Plc: Notification of relevant change to significant shareholder
DTIL

GlobeNewswire

a year ago

Caledonia Mining Corporation Plc: Notification of relevant change to significant shareholder

Investors Met With Slowing Returns on Capital At PermRock Royalty Trust (NYSE:PRT)
DTIL

Simply Wall St.

a year ago

Investors Met With Slowing Returns on Capital At PermRock Royalty Trust (NYSE:PRT)

ASP Isotopes Inc.'s (NASDAQ:ASPI) largest shareholders are individual investors with 47% ownership, insiders own 32%
DTIL

Simply Wall St.

a year ago

ASP Isotopes Inc.'s (NASDAQ:ASPI) largest shareholders are individual investors with 47% ownership, insiders own 32%

Blue Owl Unloads 9 Big Lots Stores for $51M
DTIL

Commercial Observer

a year ago

Blue Owl Unloads 9 Big Lots Stores for $51M

Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
DTIL

Business Wire

a year ago

Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

Willdan Selected for Sixth Consecutive Time to Deliver Puget Sound Energy Small Business Program
DTIL

Business Wire

a year ago

Willdan Selected for Sixth Consecutive Time to Deliver Puget Sound Energy Small Business Program

Shareholders May Be More Conservative With Northern Technologies International Corporation's (NASDAQ:NTIC) CEO Compensation For Now
DTIL

Simply Wall St.

a year ago

Shareholders May Be More Conservative With Northern Technologies International Corporation's (NASDAQ:NTIC) CEO Compensation For Now

Does The Market Have A Low Tolerance For Willdan Group, Inc.'s (NASDAQ:WLDN) Mixed Fundamentals?
DTIL

Simply Wall St.

a year ago

Does The Market Have A Low Tolerance For Willdan Group, Inc.'s (NASDAQ:WLDN) Mixed Fundamentals?

Container Store Group Insiders Lose Out As Stock Sinks To US$1.77
DTIL

Simply Wall St.

a year ago

Container Store Group Insiders Lose Out As Stock Sinks To US$1.77

Red Robin (RRGB) Exceeds Market Returns: Some Facts to Consider
DTIL

Zacks

a year ago

Red Robin (RRGB) Exceeds Market Returns: Some Facts to Consider

P3 Health Partners Reaffirms Guidance for 2023 and Announces Guidance for 2024
DTIL

Business Wire

a year ago

P3 Health Partners Reaffirms Guidance for 2023 and Announces Guidance for 2024

Tilly's (TLYS) Posts Soft Holiday Sales, Comps Decline 9%
DTIL

Zacks

a year ago

Tilly's (TLYS) Posts Soft Holiday Sales, Comps Decline 9%

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability
DTIL

GlobeNewswire

a year ago

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
DTIL

Business Wire

a year ago

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
DTIL

GlobeNewswire

a year ago

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

Share on Social Networks: